Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil. Justino, M. C. A, Linhares, A. C, Lanzieri, T. M, Miranda, Y., Mascarenhas, J. D. P, Abreu, E., Guerra, S. F S, Oliveira, A. S L, da Silva, V. B, Sanchez, N., Meyer, N., Shafi, F., Ortega-Barria, E., Soriano-Gabarró, M., & Colindres, R. E The Pediatric Infectious Disease Journal, 30(5):396–401, May, 2011. ![Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex BACKGROUND Brazil initiated universal immunization of infants with the G1P[8] human rotavirus (RV) vaccine in March 2006. This study evaluated vaccine effectiveness (VE) against severe rotavirus gastroenteritis (RVGE) hospitalizations. METHODS Matched case-control study conducted at 4 hospitals in Belém from May 2008 to May 2009. Cases were children hospitalized with RVGE age-eligible to have received 2 doses of the human RV vaccine (≥ 12 weeks of age and born after March 6, 2006). For each case, 1 neighborhood and 1 hospital control without gastroenteritis was selected, matching by birth date (± 8 and ± 6 weeks, respectively). Matched odds ratio of 2-dose RV vaccination in cases versus controls was used to estimate VE (1 - odds ratio × 100%). RESULTS Of 538 RVGE cases, 507 hospital controls and 346 neighborhood controls included, 54%, 61%, and 74% had received both RV vaccine doses. VE against RVGE hospitalization was 75.8% (95% confidence interval [CI]: 58.1-86.0) using neighborhood controls and 40.0% (95% CI: 14.2-58.1) using hospital controls. VE in children 3 to 11 months and ≥ 12 months of age was 95.7% (95% CI: 67.8-99.4) and 65.1% (95% CI: 37.2-80.6) using neighborhood controls, and 55.6% (95% CI: 12.3-77.5) and 32.1% (95% CI: -3.7-55.5) using hospital controls. G2P[4] accounted for 82.0% of RVGE hospitalizations. G2P[4]-specific VE was 75.4% (95% CI: 56.7-86.0) using neighborhood controls and 38.9% (95% CI: 11.1-58.0) using hospital controls. CONCLUSIONS Although fully heterotypic G2P[4] was the predominant RV strain, good VE was demonstrated. VE was highest in children aged 3 to 11 months. However, protection in children ≥ 12 months of age, important for optimal public health impact, was significantly sustained based on estimates obtained using neighborhood controls.
@article{justino_effectiveness_2011,
title = {Effectiveness of the monovalent {G1P}[8] human rotavirus vaccine against hospitalization for severe {G2P}[4] rotavirus gastroenteritis in {Belém}, {Brazil}},
volume = {30},
issn = {1532-0987},
url = {http://www.ncbi.nlm.nih.gov/pubmed/21150692},
doi = {10.1097/INF.0b013e3182055cc2},
abstract = {BACKGROUND
Brazil initiated universal immunization of infants with the G1P[8] human rotavirus (RV) vaccine in March 2006. This study evaluated vaccine effectiveness (VE) against severe rotavirus gastroenteritis (RVGE) hospitalizations.
METHODS
Matched case-control study conducted at 4 hospitals in Belém from May 2008 to May 2009. Cases were children hospitalized with RVGE age-eligible to have received 2 doses of the human RV vaccine (≥ 12 weeks of age and born after March 6, 2006). For each case, 1 neighborhood and 1 hospital control without gastroenteritis was selected, matching by birth date (± 8 and ± 6 weeks, respectively). Matched odds ratio of 2-dose RV vaccination in cases versus controls was used to estimate VE (1 - odds ratio × 100\%).
RESULTS
Of 538 RVGE cases, 507 hospital controls and 346 neighborhood controls included, 54\%, 61\%, and 74\% had received both RV vaccine doses. VE against RVGE hospitalization was 75.8\% (95\% confidence interval [CI]: 58.1-86.0) using neighborhood controls and 40.0\% (95\% CI: 14.2-58.1) using hospital controls. VE in children 3 to 11 months and ≥ 12 months of age was 95.7\% (95\% CI: 67.8-99.4) and 65.1\% (95\% CI: 37.2-80.6) using neighborhood controls, and 55.6\% (95\% CI: 12.3-77.5) and 32.1\% (95\% CI: -3.7-55.5) using hospital controls. G2P[4] accounted for 82.0\% of RVGE hospitalizations. G2P[4]-specific VE was 75.4\% (95\% CI: 56.7-86.0) using neighborhood controls and 38.9\% (95\% CI: 11.1-58.0) using hospital controls.
CONCLUSIONS
Although fully heterotypic G2P[4] was the predominant RV strain, good VE was demonstrated. VE was highest in children aged 3 to 11 months. However, protection in children ≥ 12 months of age, important for optimal public health impact, was significantly sustained based on estimates obtained using neighborhood controls.},
number = {5},
urldate = {2012-03-01},
journal = {The Pediatric Infectious Disease Journal},
author = {Justino, Maria Cleonice A and Linhares, Alexandre C and Lanzieri, Tatiana M and Miranda, Yllen and Mascarenhas, Joana D'arc P and Abreu, Erika and Guerra, Sylvia F S and Oliveira, Alessilva S L and da Silva, Veronilce B and Sanchez, Nervo and Meyer, Nadia and Shafi, Fakrudeen and Ortega-Barria, Eduardo and Soriano-Gabarró, Montse and Colindres, Romulo E},
month = may,
year = {2011},
pmid = {21150692},
keywords = {\#duplicates},
pages = {396--401},
}
Downloads: 0
{"_id":"6zmAqtKhhqE2F9brm","bibbaseid":"justino-linhares-lanzieri-miranda-mascarenhas-abreu-guerra-oliveira-etal-effectivenessofthemonovalentg1p8humanrotavirusvaccineagainsthospitalizationforsevereg2p4rotavirusgastroenteritisinbelmbrazil-2011","author_short":["Justino, M. C. A","Linhares, A. C","Lanzieri, T. M","Miranda, Y.","Mascarenhas, J. D. P","Abreu, E.","Guerra, S. F S","Oliveira, A. S L","da Silva, V. B","Sanchez, N.","Meyer, N.","Shafi, F.","Ortega-Barria, E.","Soriano-Gabarró, M.","Colindres, R. E"],"bibdata":{"bibtype":"article","type":"article","title":"Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil","volume":"30","issn":"1532-0987","url":"http://www.ncbi.nlm.nih.gov/pubmed/21150692","doi":"10.1097/INF.0b013e3182055cc2","abstract":"BACKGROUND Brazil initiated universal immunization of infants with the G1P[8] human rotavirus (RV) vaccine in March 2006. This study evaluated vaccine effectiveness (VE) against severe rotavirus gastroenteritis (RVGE) hospitalizations. METHODS Matched case-control study conducted at 4 hospitals in Belém from May 2008 to May 2009. Cases were children hospitalized with RVGE age-eligible to have received 2 doses of the human RV vaccine (≥ 12 weeks of age and born after March 6, 2006). For each case, 1 neighborhood and 1 hospital control without gastroenteritis was selected, matching by birth date (± 8 and ± 6 weeks, respectively). Matched odds ratio of 2-dose RV vaccination in cases versus controls was used to estimate VE (1 - odds ratio × 100%). RESULTS Of 538 RVGE cases, 507 hospital controls and 346 neighborhood controls included, 54%, 61%, and 74% had received both RV vaccine doses. VE against RVGE hospitalization was 75.8% (95% confidence interval [CI]: 58.1-86.0) using neighborhood controls and 40.0% (95% CI: 14.2-58.1) using hospital controls. VE in children 3 to 11 months and ≥ 12 months of age was 95.7% (95% CI: 67.8-99.4) and 65.1% (95% CI: 37.2-80.6) using neighborhood controls, and 55.6% (95% CI: 12.3-77.5) and 32.1% (95% CI: -3.7-55.5) using hospital controls. G2P[4] accounted for 82.0% of RVGE hospitalizations. G2P[4]-specific VE was 75.4% (95% CI: 56.7-86.0) using neighborhood controls and 38.9% (95% CI: 11.1-58.0) using hospital controls. CONCLUSIONS Although fully heterotypic G2P[4] was the predominant RV strain, good VE was demonstrated. VE was highest in children aged 3 to 11 months. However, protection in children ≥ 12 months of age, important for optimal public health impact, was significantly sustained based on estimates obtained using neighborhood controls.","number":"5","urldate":"2012-03-01","journal":"The Pediatric Infectious Disease Journal","author":[{"propositions":[],"lastnames":["Justino"],"firstnames":["Maria","Cleonice","A"],"suffixes":[]},{"propositions":[],"lastnames":["Linhares"],"firstnames":["Alexandre","C"],"suffixes":[]},{"propositions":[],"lastnames":["Lanzieri"],"firstnames":["Tatiana","M"],"suffixes":[]},{"propositions":[],"lastnames":["Miranda"],"firstnames":["Yllen"],"suffixes":[]},{"propositions":[],"lastnames":["Mascarenhas"],"firstnames":["Joana","D'arc","P"],"suffixes":[]},{"propositions":[],"lastnames":["Abreu"],"firstnames":["Erika"],"suffixes":[]},{"propositions":[],"lastnames":["Guerra"],"firstnames":["Sylvia","F","S"],"suffixes":[]},{"propositions":[],"lastnames":["Oliveira"],"firstnames":["Alessilva","S","L"],"suffixes":[]},{"propositions":["da"],"lastnames":["Silva"],"firstnames":["Veronilce","B"],"suffixes":[]},{"propositions":[],"lastnames":["Sanchez"],"firstnames":["Nervo"],"suffixes":[]},{"propositions":[],"lastnames":["Meyer"],"firstnames":["Nadia"],"suffixes":[]},{"propositions":[],"lastnames":["Shafi"],"firstnames":["Fakrudeen"],"suffixes":[]},{"propositions":[],"lastnames":["Ortega-Barria"],"firstnames":["Eduardo"],"suffixes":[]},{"propositions":[],"lastnames":["Soriano-Gabarró"],"firstnames":["Montse"],"suffixes":[]},{"propositions":[],"lastnames":["Colindres"],"firstnames":["Romulo","E"],"suffixes":[]}],"month":"May","year":"2011","pmid":"21150692","keywords":"#duplicates","pages":"396–401","bibtex":"@article{justino_effectiveness_2011,\n\ttitle = {Effectiveness of the monovalent {G1P}[8] human rotavirus vaccine against hospitalization for severe {G2P}[4] rotavirus gastroenteritis in {Belém}, {Brazil}},\n\tvolume = {30},\n\tissn = {1532-0987},\n\turl = {http://www.ncbi.nlm.nih.gov/pubmed/21150692},\n\tdoi = {10.1097/INF.0b013e3182055cc2},\n\tabstract = {BACKGROUND\n\nBrazil initiated universal immunization of infants with the G1P[8] human rotavirus (RV) vaccine in March 2006. This study evaluated vaccine effectiveness (VE) against severe rotavirus gastroenteritis (RVGE) hospitalizations.\n\n\nMETHODS\n\nMatched case-control study conducted at 4 hospitals in Belém from May 2008 to May 2009. Cases were children hospitalized with RVGE age-eligible to have received 2 doses of the human RV vaccine (≥ 12 weeks of age and born after March 6, 2006). For each case, 1 neighborhood and 1 hospital control without gastroenteritis was selected, matching by birth date (± 8 and ± 6 weeks, respectively). Matched odds ratio of 2-dose RV vaccination in cases versus controls was used to estimate VE (1 - odds ratio × 100\\%).\n\n\nRESULTS\n\nOf 538 RVGE cases, 507 hospital controls and 346 neighborhood controls included, 54\\%, 61\\%, and 74\\% had received both RV vaccine doses. VE against RVGE hospitalization was 75.8\\% (95\\% confidence interval [CI]: 58.1-86.0) using neighborhood controls and 40.0\\% (95\\% CI: 14.2-58.1) using hospital controls. VE in children 3 to 11 months and ≥ 12 months of age was 95.7\\% (95\\% CI: 67.8-99.4) and 65.1\\% (95\\% CI: 37.2-80.6) using neighborhood controls, and 55.6\\% (95\\% CI: 12.3-77.5) and 32.1\\% (95\\% CI: -3.7-55.5) using hospital controls. G2P[4] accounted for 82.0\\% of RVGE hospitalizations. G2P[4]-specific VE was 75.4\\% (95\\% CI: 56.7-86.0) using neighborhood controls and 38.9\\% (95\\% CI: 11.1-58.0) using hospital controls.\n\n\nCONCLUSIONS\n\nAlthough fully heterotypic G2P[4] was the predominant RV strain, good VE was demonstrated. VE was highest in children aged 3 to 11 months. However, protection in children ≥ 12 months of age, important for optimal public health impact, was significantly sustained based on estimates obtained using neighborhood controls.},\n\tnumber = {5},\n\turldate = {2012-03-01},\n\tjournal = {The Pediatric Infectious Disease Journal},\n\tauthor = {Justino, Maria Cleonice A and Linhares, Alexandre C and Lanzieri, Tatiana M and Miranda, Yllen and Mascarenhas, Joana D'arc P and Abreu, Erika and Guerra, Sylvia F S and Oliveira, Alessilva S L and da Silva, Veronilce B and Sanchez, Nervo and Meyer, Nadia and Shafi, Fakrudeen and Ortega-Barria, Eduardo and Soriano-Gabarró, Montse and Colindres, Romulo E},\n\tmonth = may,\n\tyear = {2011},\n\tpmid = {21150692},\n\tkeywords = {\\#duplicates},\n\tpages = {396--401},\n}\n\n","author_short":["Justino, M. C. A","Linhares, A. C","Lanzieri, T. M","Miranda, Y.","Mascarenhas, J. D. P","Abreu, E.","Guerra, S. F S","Oliveira, A. S L","da Silva, V. B","Sanchez, N.","Meyer, N.","Shafi, F.","Ortega-Barria, E.","Soriano-Gabarró, M.","Colindres, R. E"],"key":"justino_effectiveness_2011","id":"justino_effectiveness_2011","bibbaseid":"justino-linhares-lanzieri-miranda-mascarenhas-abreu-guerra-oliveira-etal-effectivenessofthemonovalentg1p8humanrotavirusvaccineagainsthospitalizationforsevereg2p4rotavirusgastroenteritisinbelmbrazil-2011","role":"author","urls":{"Paper":"http://www.ncbi.nlm.nih.gov/pubmed/21150692"},"keyword":["#duplicates"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/robin.marlow","dataSources":["ix72eqAAMGCuupBaz"],"keywords":["#duplicates"],"search_terms":["effectiveness","monovalent","g1p","human","rotavirus","vaccine","against","hospitalization","severe","g2p","rotavirus","gastroenteritis","bel","brazil","justino","linhares","lanzieri","miranda","mascarenhas","abreu","guerra","oliveira","da silva","sanchez","meyer","shafi","ortega-barria","soriano-gabarró","colindres"],"title":"Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil","year":2011}